The Bill & Melinda Gates Foundation, Wellcome and Mastercard have announced commitment totaling $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments.
The partners are committed to equitable access, including making products available and affordable in low-resource settings. The Gates Foundation and Wellcome are each contributing up to $50 million, and the Mastercard Impact Fund has committed up to $25 million to catalyze the initial work of the accelerator. The Gates Foundation’s funding is part of its $100 million commitment to the COVID-19 response announced last month.
(Ad) Still, finding it difficult to find new grants and donors to support your work? No way to easily search and identify upcoming funding opportunities? No idea how to raise funds? We have a solution for you. Our Premium Membership service answers all your questions. Learn more.
The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and re-purposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. Currently there are no broad-spectrum antivirals or immunotherapies available for the fight against emerging pathogens, and none approved for use on COVID-19.
Chief Executive Officer of the Bill & Melinda Gates Foundation, Mark Suzman said, “Viruses like COVID-19 spread rapidly, but the development of vaccines and treatments to stop them moves slowly. If we want to make the world safe from outbreaks like COVID-19, particularly for those most vulnerable, then we need to find a way to make research and development move faster. That requires governments, private enterprise, and philanthropic organizations to act quickly to fund R&D.”
(Ad) Too many advertisements on this website? Get an ad-free and fully optimized website experience to find grants and donors of your interest. Premium Membership service offers a clean and user-friendly interface for you to raise funds successfully! Learn more.
Vice Chairman of Mastercard, Mike Froman said, “We’re proud to join this crucial effort to combat COVID-19 in furtherance of our commitment to inclusive growth. This global challenge not only represents a risk to the health and safety of populations all over the world, but also poses a potential disruption to the economic vitality of millions of people, businesses, and organizations worldwide. Our experience with financial inclusion shows us the importance of building a network of parties who bring not only their capital, but complementary assets and skill sets to the table, and we welcome other partners concerned about inclusive growth to join this effort.”
Therapeutics Accelerator will coordinate R&D efforts and remove barriers to drug development and scale-up to address the epidemic. It will work with the World Health Organization, government and private sector funders and organizations, as well as the global regulatory and policy-setting institutions.
(Ad) Premium Membership offers unlimited search options to find your grants and donors. Search by country or thematic area of your work interest or even by keyword. View the number of open grants for your country. on a Google Map. Keep a watch on grant deadlines through a calendar. Learn more.
The Accelerator will have an end-to-end focus, from drug pipeline development through manufacturing and scale-up. By sharing research, coordinating investments, and pooling resources, these efforts can help to accelerate research.
By providing fast and flexible funding at key stages of the development process, the Accelerator will de-risk the pathway for new drugs and biologics for COVID-19 and future epidemic threats, ensuring access in lower-resource countries.
(Ad) Too many emails about grants, but too few leads? Join Premium and use our Specific Email Alerts feature where you can select your country/countries and thematic areas of work interest and receive grant information accordingly. Learn more.
The COVID-19 Therapeutics Accelerator will operate jointly as an initiative of the funders, drawing on expertise from inside and outside their organizations. The Accelerator will pursue several aspects of the development cycle to streamline the pathway from candidate product to clinical assessment, use, and manufacturing.
To identify candidate compounds, the Accelerator will take a three-pronged approach: testing approved drugs for activity against COVID-19, screening libraries of thousands of compounds with confirmed safety data and considering new investigational compounds and monoclonal antibodies.
(Ad) Our Premium Donor Search feature works like a mini-search engine. As soon as you define the search criteria and click on search, it scans the internet for the best possible matches of donor agencies based according to your interest and presents a list that you need. Learn more.
Drugs or monoclonal antibodies that pass initial screening would then be developed by an industry partner. The biotech and pharmaceutical industries will be critical partners, bringing their compound libraries and clinical data to the collaboration and lending commercialization and other expertise that will be required to scale up successful drugs and monoclonal antibodies.
Director of Wellcome, Dr. Jeremy Farrar said, “This virus is an unprecedented global threat, and one for which we must propel international partnerships to develop treatments, rapid diagnostics, and vaccines. Science is moving at a phenomenal pace against COVID-19, but to get ahead of this epidemic we need greater investment and to ensure research co-ordination. The Therapeutics Accelerator will allow us to do this for potential treatments with support for research, development, assessment, and manufacturing.”
(Ad) Lots of grant opportunities but no idea how to write a proposal to apply for them? We have a huge collection of sample proposals available only for Premium Members. You can view these proposals and even request for download. Get ideas from other successful grantees and write your proposal quickly. Learn more.
“COVID-19 is an extremely challenging virus, but we’ve proved that through collaborating across borders we can tackle emerging infectious diseases. We must strive to strengthen efforts in the face of COVID-19, and in doing so, continue to make sure advances are accessible and affordable to all. Investing now, at scale, at risk and as a collective global effort is vital if we are to change the course of this epidemic. We welcome others to join us in this effort.”
In parallel to the development of the COVID-19 drug pipeline, the Accelerator will work with regulators to align criteria and develop manufacturing capacity with industry. An accelerated pathway to bringing effective treatments to patients is around one year for products that have current regulatory approval or candidates with existing clinical data. The timeline would be longer for compounds further upstream in the pipeline that have limited existing clinical data.
While antiviral drugs are approved to lessen the severity of seasonal flu and treat HIV, among other viral diseases, none have demonstrated efficacy against the current epidemic. One reason for the lack of effective treatments is that products may not have an immediate market, which can slow or prevent their research and commercial development.
The COVID-19 Therapeutics Accelerator is designed to help by bringing together resources and expertise to lower the financial and technical risk for academia, biotech, and pharmaceutical companies, while ensuring that these products are accessible and affordable to people in low-resource settings. The expertise of pharmaceutical companies will be critical in identifying, researching, and commercializing successful drugs.
About the Bill & Melinda Gates Foundation
(Ad) A massive library of Downloadable Ebooks, covering a range of how-to topics from fundraising, proposal writing, grant listings, donor listings to NGO management. Learn more.
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life.
(Ad) How will you feel when you view grants for all countries around the world? fundsforNGOs Premium has a World Map of Grants that offers open and live grants for all the countries in one single view. Click on any country, and you can view the latest grants updated in real-time. Learn more.
Wellcome exists to improve health by helping great ideas to thrive. They support researchers, take on big health challenges, they campaign for better science, and help everyone get involved with science and health research. They are a politically and financially independent foundation.
(Ad) There are so many NGO Jobs, but what about my country and area of work? fundsforNGOs Premium has a "Jobs Database" where you can not only search jobs but also receive job alerts in your email based on your country (or countries) and areas of your profession. Learn more.
Mastercard is a global technology company in the payments industry. Our mission is to connect and power an inclusive, digital economy that benefits everyone, everywhere by making transactions safe, simple, smart, and accessible. Using secure data and networks, partnerships and passion, our innovations and solutions help individuals, financial institutions, governments, and businesses realize their greatest potential.